Detalles de la búsqueda
1.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30297397
2.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res
; 19(1): 16, 2017 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183321
3.
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
Br J Cancer
; 113(8): 1225-33, 2015 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26379078
4.
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Breast Cancer Res
; 16(3): R50, 2014 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24887458
5.
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Nat Med
; 13(9): 1070-7, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17767167
6.
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.
Proc Natl Acad Sci U S A
; 108(43): E943-51, 2011 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-21949371
7.
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Cancer Invest
; 30(10): 727-31, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23061802
8.
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Mol Cancer Res
; 7(4): 511-22, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19372580
9.
Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays.
Mol Cancer Ther
; 7(12): 3695-706, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19056674
10.
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
PLoS One
; 14(5): e0216864, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125352
11.
Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Cancer Res
; 66(1): 283-9, 2006 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16397241
12.
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Nat Med
; 24(9): 1441-1448, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30082870
13.
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.
NPJ Precis Oncol
; 2(1): 7, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29872725
14.
Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Oral Oncol
; 67: 52-60, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28351581
15.
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
Clin Cancer Res
; 23(17): 5238-5245, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28536307
16.
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
J Clin Oncol
; 23(25): 5900-9, 2005 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16043828
17.
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Clin Cancer Res
; 11(24 Pt 1): 8686-98, 2005 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16361555
18.
Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
PLoS One
; 11(11): e0165856, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27846280
19.
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Nat Commun
; 7: 11579, 2016 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27174596
20.
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
Breast Cancer Res
; 7(6): R953-64, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16280042